Therapeutic approaches and vaccination in fighting COVID-19 infections: A review

Küçük Resim Yok

Tarih

2022

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Elsevier Inc.

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals. © 2022

Açıklama

Anahtar Kelimeler

Antiviral agents, COVID-19, Pandemics, Pneumonia, SARS-CoV-2, Vaccines, 2019ncov hr 2p, angiotensin converting enzyme 2, anti-SARS-CoV-2 agent, antibiotic agent, bamlanivimab, camostat mesilate, casirivimab plus imdevimab, chloroquine, coronavirus spike glycoprotein, corticosteroid, dalbavancin, danoprevir, etesevimab, favipiravir, hydroxychloroquine, immunomodulating agent, inactivated vaccine, interferon, ivermectin, lopinavir, metformin, molnupiravir, nafamstat mesilate, nelfinavir, nirmatrelvir, peptide, recombinant angiotensin converting enzyme 2, regen cov, remdesivir, RNA vaccine, SARS-CoV-2 antibody, SARS-CoV-2 convalescent plasma, SARS-CoV-2 vaccine, sid 26681509, siltuximab, sintilimab, sotrovimab, subunit vaccine, thioctic acid, tocilizumab, umifenovir, unclassified drug, vector vaccine, antibiotic therapy, coronavirus disease 2019, corticosteroid therapy, human, nonhuman, Review, Severe acute respiratory syndrome coronavirus 2, vaccination, virus cell membrane fusion, virus endocytosis, virus entry

Kaynak

Gene Reports

WoS Q Değeri

Scopus Q Değeri

Q4

Cilt

27

Sayı

Künye